

	<b>Actors</b>	<b>Objects</b>	<b>Processes</b>	<b>Impacts</b>
<b>Transparency</b>	<b>TA1:</b> This project is a collaboration between two partners: the Institute of Data Science (IDS) and Maastricht University Hospital (MUMC+). The main involved actors are J. Doe as Principal investigator of IDS and X.White as Principal Investigator of MUMC+. Heart failure patients from MUMC+ are involved via a clinical trial.	<b>TO1:</b> In two phases the project creates Output1: Predictive models for heart failure Output2: A trial to externally evaluate the defined models. <b>TO4:</b> The metadata contains the features and their corresponding descriptions: PatientID, Documents, Date, Department, Caregiver, Outcome	<b>TP1:</b> <i>Phase 1:</i> The data is extracted from the electronic records and anonymized by MUMC+..At IDS, the data is selected, cleaned and analysed with machine learning models (Logistic regression, LSTM and SVM). The process is re-iterated to optimise performance. <i>Phase 2:</i> Using a randomised clinical trial, patients are selected to be involved in this study 100 patients are randomly assigned to standard care or standard care with the addition of the predictive model.	<b>TI6:</b> Potential Misuses can be: 1. Doctors may rely too much on the produced predictive algorithm. 2. Some cases might end up with less care because the algorithm misclassified them. 3. If insurance companies are able to reproduce the same or a similar solution this might have implications towards premiums of the patients that we are trying to help the most
<b>Accountability</b>	<b>AA3:</b> UM maintains a data processing of personal data in a registry. The project was registered by the principal investigators with the Data Protection Officer (fg@maastrichtuniversity.nl) In case of a data breach the project team needs to report via the ICTS Servicedesk under "Report possible UM data leak" <sup>1</sup> .	<b>AO5:</b> No specific biases were identified in the data. Some bias may be present due to differences in healthcare processes. This means that the findings might not be reflective of the general heart failure population and can only be captured if further validations are performed.. Moreover 85% of the cohort is above 65 years old. The gender ratio is 55% male.	<b>AP2:</b> In accordance with the ethical approval nurses support the data collection process. The training and instructions are provided by the scientist in the post-doc role. The research assistant and PhD will work on the identification of representative data. The whole team contributes to the development of the models. The findings are reported by the whole team for domain experts, the research and medical community. Moreover continuous medical and technical input is provided from the principal investigators.	<b>AI:2</b> Outcomes are reported to all stakeholders. Scientific reports are published in open-science venues and a FAIR data sharing approach is used to enable scientific reproducibility of the findings. Medical practitioners use graphical explanations to comprehend the advice given by the predictive algorithm. Patients are reached via press releases. . Press releases are shared via the communication office Maastricht University.
<b>Privacy/ Confidentiality</b>	<b>PA1:</b> Yes, in Phase 2 we use informed consent to enroll patients. Given that the study is in the Netherlands, the informed consent is in Dutch <sup>2</sup> (by legal requirement).	<b>PO1:</b> In phase 1 the data are anonymised by the data collector. In phase 2 the data was anonymised using random ids, and removing personal identifiable data fields.	<b>PP4:</b> Sensitive fields (personal identifiable fields) such as patient names, patient id and personal identifier numbers are replaced with an anonymized id. Documents are also analysed for personal identifying information, however this process does not guarantee a full anonymisation.	<b>PI2:</b> Yes, privacy may be impacted if data is shared without a confidentiality agreement. We are unable to guarantee a full anonymisation of the documents (e.g. dr. notes). Names or other identifying elements might be present after cleaning the data.
<b>Societal Values</b>	<b>SA3:</b> Researchers will follow the Netherlands Code of Conduct for Research Integrity <sup>2</sup> and moreover, the Integrity and behavior code <sup>3</sup> for ICT staff at Maastricht University.	<b>SO4:</b> A data sharing agreement has been signed. If the cooperation extends to others, the new partner will comply with the Dutch rules and norms. I.e, A Chinese collaborator, it will comply with GDPR.	<b>SP6:</b> Phase 1: A retrospective cohort is used to define predictive models. We assume that gender distribution is reflective of the overall disease distribution in the area. There are more male than female subjects in the cohort ( respectively 55%, 45%). To avoid bias we check the prediction accuracy per gender. Cultural and population bias are not present.	<b>SI2:</b> No side-effects are identified in patients as they receive standard care. We will communicate to doctors the limitations of the algorithm. To overcome the back-box effect of the algorithm, a user interface visualises the relevant features and shows three similar cases.

<sup>1</sup> <https://servicedesk.icts.maastrichtuniversity.nl/tas/public/ssp/>

<sup>2</sup> [https://www.universiteitennederland.nl/files/documents/Netherlands Code of Conduct for Research Integrity 2018.pdf](https://www.universiteitennederland.nl/files/documents/Netherlands%20Code%20of%20Conduct%20for%20Research%20Integrity%202018.pdf)

<sup>3</sup> [https://www.maastrichtuniversity.nl/file/7429/download?token=I\\_9r4Ek7](https://www.maastrichtuniversity.nl/file/7429/download?token=I_9r4Ek7)